MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
06 sept. 2023 07h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11 ZUG, Switzerland, September 6, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage...
MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply
03 mai 2023 06h45 HE
|
MoonLake Immunotherapeutics AG
ZUG, Switzerland, May 3, 2023 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases,...
MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today
19 avr. 2023 08h16 HE
|
MoonLake Immunotherapeutics AG
ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases,...
Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones
04 avr. 2023 07h00 HE
|
Oculis SA
ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing
22 mars 2023 07h00 HE
|
Oculis SA
ZUG, Switzerland, and BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye...
UK marketing authorisations for IOPIDINE® (apraclonidine) fully transferred to Essential Pharma as change in UK NICE guidelines for glaucoma treatment expected to lead to increase in patients’ need for product
15 déc. 2022 07h06 HE
|
Essential Pharma
UK marketing authorisations for IOPIDINE® (apraclonidine) fully transferred to Essential Pharma as change in UK NICE guidelines for glaucoma treatment expected to lead to increase in patients’ need...
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis
14 déc. 2022 08h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis Phase 2 study represents an important step in psoriatic arthritis...
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH
26 juil. 2022 08h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH ZUG, Switzerland, July 26, 2022 – MoonLake Immunotherapeutics AG (MoonLake; Nasdaq:...